1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Kazia Therapeutics Limited
  6. News
  7. Summary
    KZA   AU000000KZA9

KAZIA THERAPEUTICS LIMITED

(KZA)
  Report
Delayed Australian Stock Exchange  -  11:52 2022-06-23 pm EDT
0.6600 AUD   +5.60%
08:06aKazia educational webinar on paxalisib in childhood brain cancer
AQ
06/23KAZIA THERAPEUTICS : presentation on paxalisib for childhood brain cancer
PU
06/22TRANSCRIPT : Kazia Therapeutics Limited - Special Call
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Kazia Therapeutics : presentation on paxalisib for childhood brain cancer

06/23/2022 | 04:15am EDT

ASX RELEASE

23 June 2022

KAZIA EDUCATIONAL WEBINAR ON PAXALISIB IN CHILDHOOD BRAIN CANCER

Sydney, 23 June 2022 - Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology- focused drug development company, is pleased to provide a presentation on paxalisib in childhood brain cancer, featuring Dr James Garner, Associate Professor Matt Dun and Dr John Friend. A copy of the webinar will be made available in the media section of our website.

https://www.kaziatherapeutics.com/site/media-centre/overview

For More Information, Please Contact:-

In the United States:

In Australia:

Joe Green

Jane Lowe

Edison Investor Relations

IR Department

jgreen@edisongroup.com

jane.lowe@irdepartment.com.au

Phone: +1 646-653-7030

Phone: +61 411 117 774

About Kazia Therapeutics Limited

Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA) is an oncology-focused drug development company, based in Sydney, Australia.

Our lead program is paxalisib, a brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat glioblastoma, the most common and most aggressive form of primary brain cancer in adults. Licensed from Genentech in late 2016, paxalisib commenced recruitment to GBM AGILE, a pivotal study in glioblastoma, in January 2021. Seven additional studies are active in various forms of brain cancer. Paxalisib was granted Orphan Drug Designation for glioblastoma by the US FDA in February 2018, and Fast Track Designation for glioblastoma by the US FDA in August 2020. In addition, paxalisib was granted Rare Pediatric Disease Designation and Orphan Designation by the US FDA for DIPG in August 2020, and Orphan Designation for AT/RT in June 2022.

Board of Directors

Mr Iain Ross Chairman, Non-Executive Director

Mr Bryce Carmine Non-Executive Director

Mr Steven Coffey Non-Executive Director

Dr James Garner Chief Executive Officer, Managing Director

Three International Towers, Level 24, 300 Barangaroo Avenue, Sydney NSW 2000

Kazia is also developing EVT801, a small-molecule inhibitor of VEGFR3, which was licensed from Evotec SE in April 2021. Preclinical data has shown EVT801 to be active against a broad range of tumour types and has provided compelling evidence of synergy with immuno- oncology agents. A phase I study commenced recruitment in November 2021.

For more information, please visit www.kaziatherapeutics.comor follow us on Twitter @KaziaTx.

This document was authorized for release to the ASX by James Garner, Chief Executive Officer, Managing Director.

Paxalisib in

Childhood Brain Cancer

Educational Webinar

22 June 2022

ASX: KZA | NASDAQ: KZIA | Twitter: @KaziaTx

Forward-Looking Statements

This presentation contains forward-lookingstatements within the meaning of the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve substantial risks and uncertainties, not all of which may be known at the time. All statements contained in this presentation, other than statements of historical fact, including statements regarding our strategy, research and development plans, collaborations, future operations, future financial position, future revenues, projected costs, prospects, plans, and objectives of management, are forward-looking statements. Not all forward-looking statements in this presentation are explicitly identified as such.

Many factors could cause the actual results of the Company to differ materially from the results expressed or implied herein, and you should not place undue reliance on the forward-looking statements. Factors which could change the Company's expected outcomes include, without limitation, our ability to: advance the development of our programs, and to do so within any timelines that may be indicated herein; the safety and efficacy of our drug development candidates; our ability to replicate experimental data; the ongoing validity of patents covering our drug development candidates, and our freedom to operate under third party intellectual property; our ability to obtain necessary regulatory approvals; our ability to enter into and maintain partnerships, collaborations, and other business relationships necessary to the progression of our drug development candidates; the timely availability of necessary capital to pursue our business objectives; and our ability to attract and retain qualified personnel; changes from anticipated levels of customer acceptance of existing and new products and services and other factors.

Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can therefore be no assurance that such expectations will prove to be correct. The Company has no obligation as a result of this presentation to clinical trial outcomes, sales, partnerships, future international, national or regional economic and competitive conditions, changes in relationships with customers, access to capital, difficulties in developing and marketing new products and services, or marketing existing products.

In addition, the extent to which the COVID-19 outbreak continues to impact our workforce and our discovery research, supply chain and clinical trial

operations activities, and the operations of the third parties on which we rely, will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration and severity of the outbreak, additional or modified government actions, and the actions that may be required to contain the virus or treat its impact.

Any forward-looking statements contained in this presentation speak only as of the date this presentation is made, and we expressly disclaim any obligation to update any forward-looking statements, whether because of new information, future events or otherwise.

1

Dr James Garner

Associate Professor Matt Dun

Dr John Friend

Chief Executive Officer

Group Leader, Cancer Research

Chief Medical Officer

Signalling Group

Kazia Therapeutics Limited

Hunter Medical Research Institute

Kazia Therapeutics Limited

University of Newcastle, Australia

2

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

Kazia Therapeutics Limited published this content on 23 June 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 23 June 2022 08:14:04 UTC.


© Publicnow 2022
All news about KAZIA THERAPEUTICS LIMITED
08:06aKazia educational webinar on paxalisib in childhood brain cancer
AQ
06/23KAZIA THERAPEUTICS : presentation on paxalisib for childhood brain cancer
PU
06/22TRANSCRIPT : Kazia Therapeutics Limited - Special Call
CI
06/17KAZIA THERAPEUTICS : US FDA AWARDS ORPHAN DRUG DESIGNATION (ODD) TO PAXALISIB FOR AT/RT, A..
PU
06/17Kazia Therapeutics Gets FDA Orphan Drug Designation for Paxalisib for Rare Form of Chil..
MT
06/17KAZIA THERAPEUTICS : Application for quotation of securities - KZA
PU
06/17Australian Shares Continue Six-Day Losing Streak; Humm and Latitude Financial Terminate..
MT
06/16Kazia Therapeutics Secures US FDA Orphan Drug Designation for Brain Cancer in Children
MT
06/14Kazia Therapeutics Limited - POSITIVE DATA FOR PAXALISIB IN TWO CHILDHOOD BRAIN CANCERS..
AQ
06/14Kazia Therapeutics' Brain Tumor Medication Resolves Disease Symptoms, Extends Survival ..
MT
More news
Analyst Recommendations on KAZIA THERAPEUTICS LIMITED
More recommendations
Financials
Sales 2022 0,01 M 0,01 M 0,01 M
Net income 2022 -26,8 M -18,5 M -18,5 M
Net Debt 2022 - - -
P/E ratio 2022 -3,05x
Yield 2022 -
Capitalization 88,9 M 61,4 M 61,4 M
Capi. / Sales 2022 9 877x
EV / Sales 2023 6,40x
Nbr of Employees -
Free-Float 80,8%
Chart KAZIA THERAPEUTICS LIMITED
Duration : Period :
Kazia Therapeutics Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends KAZIA THERAPEUTICS LIMITED
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Last Close Price 0,63 AUD
Average target price 1,90 AUD
Spread / Average Target 204%
EPS Revisions
Managers and Directors
James Garner Chief Executive Officer, MD & Executive Director
Gabrielle Heaton Director-Finance & Administration
Karen R. Krumeich Chief Financial Officer
Iain Gladstone Ross Chairman
John E. Friend Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
KAZIA THERAPEUTICS LIMITED-47.41%58
MODERNA, INC.-43.59%54 123
IQVIA HOLDINGS INC.-25.02%38 185
LONZA GROUP AG-35.92%38 059
SEAGEN INC.12.55%31 230
ALNYLAM PHARMACEUTICALS, INC.-13.73%17 102